Market Research Reports, Inc.

The Systemic Lupus Erythematosus (SLE) Treatment Market to Reach $1.1 Billion by 2022

The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years.


Lewes, DE -- (SBWIRE) -- 03/18/2014 -- The Systemic Lupus Erythematosus (SLE) treatment market in the seven major countries (7MM) will increase significantly in value over the coming years, jumping from approximately $473.6 million in 2012 to $1.1 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 9.36%, according to a recent report.

The report* also states that the total revenues for Lupus Nephritis (LN) in the 7MM – the US, France, Germany, Italy, Spain, the UK and Japan – will climb from an estimated $216.6 million in 2012 to $505.9 million by the end of the forecast period, representing a slightly lower CAGR of 8.86%.

Research attributes the anticipated growth in both markets to the higher uptake of Benlysta and off-label Rituxan, along with the introduction of new biological therapies and overall increase in prevalent cases of SLE and LN across the 7MM during the forecast period.

Analyst for this report, says: “The approval of Benlysta in 2011, which made it the first product to gain marketing approval for SLE patients in more than 50 years, has paved the way for the introduction of new disease-modifying treatments and reignited the interest of pharmaceutical developers in this therapy area.”

Currently, all late-stage pipeline products for lupus are biologic drugs that will compete with Benlysta and offer new treatment options to patients. These include Anthera Pharmaceuticals’ blisibimod, Eli Lilly’s tabalumab and Merck Serono’s atacicept, which are anti-BLyS therapies.

Also in the late-stage pipeline are UCB’s epratuzumab, ImmuPharma’s Lupuzor and Bristol-Myers Squibb’s Orencia, which all boast novel mechanisms of action.

Analyst continues: “With a number of products still in development, the lupus therapeutics market remains characterized by significant unmet needs. LN patients are greatly underserved with currently available treatments, and the mortality of all lupus patients remains high when compared with the general population.

“As a result, the most pressing unmet need is for the development of new therapies that boast more positive safety profiles, offer potent clinical benefits to patients and expand their treatment options,” the analyst concludes.

*For detailed TOC and pricing please visit:

Browse other reports in our diseases section:

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at:

Follow us on Vimeo :